Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Slightly Bearish -20

Becton Dickinson clear analyst focus, shares trade steadily in the S&P 500 - Ad-hoc-news.de

AI-generated analysis

πŸ“‰ Becton Dickinson shares trade around $145.43, representing a roughly 49% decline from the July 2023 all-time high of $287.32.

🏦 Bank of America trimmed its price target in mid-June 2026 due to medtech headwinds and unfavorable risk-reward profiles for procedure-dependent lines.

πŸ“Š Consensus data shows a majority of analysts still rate Becton Dickinson as Buy or Outperform with targets above current levels.

⚠️ Several brokers have adopted cautious wording regarding hospital capital budgets and procedure volumes affecting near-term growth.

πŸ’Ό The company operates across three segments: BD Medical, BD Life Sciences, and BD Interventional serving global healthcare needs.

πŸ“ˆ Investors are closely monitoring the next earnings date to assess potential recovery from the muted three-year performance.

🌍 European trading platforms show shares quoted around 123 euros, reflecting the same underlying valuation trends as U.S. markets.

Bullish Signals
  • A solid majority of covering houses still rate Becton Dickinson at Buy or Outperform according to consensus data.
  • The average 12-month price target sits noticeably above the current share price, pointing to perceived upside from current levels.
  • Bank of America continues to view BD as a core name within large-cap medical technology despite recent target cuts.
Risk Factors
  • Becton Dickinson shares have experienced a muted three-year performance versus the wider S&P 500 index.
  • Bank of America cited ongoing medtech headwinds and a less favorable risk-reward profile for some procedure-dependent product lines.
  • Several brokers have adopted more cautious wording around hospital capital budgets and procedure volumes, which could weigh on near-term growth.
Full Analysis
Becton Dickinson (BDX) shares are trading in the mid-$140 range on the NYSE, reflecting a roughly 49% decline from their July 2023 peak of $287.32. This muted performance over the last three years contrasts with the broader S&P 500 index, prompting renewed analyst attention regarding the company's valuation and future prospects. Bank of America recently trimmed its price target for Becton Dickinson in mid-June 2026, citing ongoing headwinds within the medical technology sector and a less favorable risk-reward profile for specific procedure-dependent product lines. Despite this caution, the bank maintains its view of BD as a core large-cap name with a diversified portfolio spanning diagnostics, medical devices, and interventional products. Consensus data from MarketScreener indicates that a solid majority of analysts still rate Becton Dickinson as Buy or Outperform, with average 12-month price targets sitting noticeably above the current share price. However, several brokers have adopted more cautious language regarding hospital capital budgets and procedure volumes, which could weigh on near-term growth. The company generates revenue across three main segments: BD Medical, BD Life Sciences, and BD Interventional, supplying hospitals and clinicians globally with devices for medication management and diagnostics. Investors are currently tracking the next earnings date to determine if the stock can recover from its significant discount to all-time highs amidst normalized procedure growth.